XERS logo

XERIS BIOPHARMA HOLDINGS INC

XERSNASDAQ
πŸ† #1554 by market capEarnings Mar 1 Β· PostUS Equity
β€”β€”
Quote unavailable
πŸ””
Track XERS
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$3.10B
Small Cap
πŸ“ˆRevenue Growth (YoY)
43.7%
High Growth
πŸ“ŠGross Margin
84.4%
High
πŸ’΅FCF Margin
19.7%
Healthy
βš–οΈP/S Ratio
8.4x
Elevated
Otter Score
76
Strong
No chart data available for XERS.

Trading Snapshot

Day Range
β€”
52-Week Range
$5.25 – $17.28
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
182.7M
Next Earnings
2027-03-01

Fundamentals Snapshot

Annual Revenue
$292M
Last Q Revenue
$107M
P/E Ratio
-423.2
P/S Ratio
8.4x
EPS (TTM)
$-0.04
Dividend Yield
0.00%
Dilution (1yr)
+20.8%
XERS logo

XERIS BIOPHARMA HOLDINGS INC

XERS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$292Mβ–² +43.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
81.7%β–Ό βˆ’0.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$25Mβ–Ό βˆ’174.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$28Mβ–Ό βˆ’173.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
180.1Mβ–² +20.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$73Mβ–² +$273M YoY
StockOtter Β· stockotter.space

About XERIS BIOPHARMA HOLDINGS INC

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100
Analyst data unavailable.

Latest News & Updates

News unavailable.